Loading
A phase 3 trial of Encorafenib, Binimetinib in melanoma, run by Pierre Fabre Medicament, active and no longer recruiting.
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. is a phase 3 interventional study registered as NCT05270044 by Pierre Fabre Medicament, with 815 participants planned, started 2022-05-02 and due to reach its primary completion in 2027-03-31. Interventions recorded: Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Melanoma.
Shares Pierre Fabre, Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma.
Shares Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, Encorafenib, BRAF V600-mutant melanoma, Melanoma.
Shares Stage IIB and IIC melanoma, BRAF V600-mutant melanoma, Melanoma.
Shares BRAF V600-mutant melanoma, Melanoma, Small-molecule kinase inhibitors.
Shares BRAF V600-mutant melanoma, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/